January 9, 2018 in Blog, News from Our Companies

Rimidi names Josh Claman as CEO

Post placeholder image
Headshot of Josh Claman
Josh Claman

Rimidi, a digital health company that provides software and clinical analytics for chronic disease management, appointed Josh Claman as president and chief executive officer. Dr. Lucienne M. Ide, Rimidi’s co-founder and immediate past CEO, will continue to serve as chairwoman of Rimidi’s board of directors.

Rimidi is a startup in the Advanced Technology Development Center’s ATDC Signature portfolio of companies.

“Josh is going to take Rimidi to the next level,” Ide said. “He has a stellar leadership reputation and brings a wealth of functional experiences, ranging from leading services, consulting, sales, marketing, and operational organizations.

“He is the right person to lead Rimidi to the next stage of growth.”

Claman has more than 25 years leading technology businesses in Asia, Europe and the Americas. His industry experiences include his time at Dell, where he managed multi-billion-dollar business units, to his role as president of one of the largest advertising technology companies in the United States. Most recently, he had been chief business officer of one of the largest global 3D printing companies.

“I’m incredibly excited to join the Rimidi team,” Claman said. “Rimidi is transforming the delivery of healthcare for individuals with chronic conditions and the healthcare providers who serve them. I have always been a strong advocate for the promise of technology, and know that Rimidi is going to play an important role in the digital revolution in healthcare.”

Ide will remain actively involved in the company as chairman of the board of directors. She will continue to provide long-term strategy, oversee clinical product development, and lead innovation initiatives. Ide has served as Rimidi’s president and CEO for the past 6 years and is a thought leader in healthcare technology.

About Diabetes:

Approximately 30 million Americans and an estimated 425 million adults worldwide have diabetes. Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases in the United States. Diabetes is a chronic disease that occurs when the body does not properly produce or use the hormone insulin.

About Rimidi:

Rimidi is an Atlanta-based, digital health company bringing to market data analytics and disease management solutions. Its flagship product, Diabetes+Me™, is a software solution focused on empowering quality diabetes care for healthcare organizations, providers, and people living with diabetes. For more information, visit Rimidi-Serious Hope for Healthcare.

By browsing this website, you agree to our privacy policy.
I Agree